Market news

MDxHealth now carries a refreshed fair value estimate of US$1.80, down from US$2.20, which marks about an 18% reduction in the central price target used in the latest analyst model. This shift reflects recent commentary that weighs progress in prostate cancer diagnostics and balance sheet clean up against dilution from new equity and questions about execution after the Resolve wind down. As you read on, you will see how these moving parts shape the evolving MDxHealth story and what to watch...

Detailed price information for Bristol-Myers Squibb (BMY-N) from The Globe and Mail including charting and trades.

Motley Fool Press Release.

Detailed price information for Mdxhealth Sa ADR (MDXH-Q) from The Globe and Mail including charting and trades.

Moby summary of MDxHealth S.A.'s Q2 2026 earnings call

Real-time index price for TSX Venture Composite Index (JX), along with buy or sell indicators, analysis, charts, historical performance, news and more

MDxHealth SA (MDXH) delivered earnings and revenue surprises of -50.00% and +5.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

MDxHealth SA (MDXH) delivers its largest quarter-over-quarter revenue acceleration in company history while eliminating a $10.4 million liability and strengthening its balance sheet.

Second quarter revenue growth of 16% to $27.2 millionConference call with Q&A today at 4:30 PM EST / 22:30 CET

Company to Host Conference Call with Live Q&A, August 13, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – July 30, 2026 (GlobeNewswire) –...